摘要：In 1977, the World Health Organization (WHO) published its first Model List of Essential Medicines. 1 This year, the Expert Committee for the Selection and Us e of Medicines will consider requests to include high-cost medicines for can- cer, hepatitis C, multidrug-resistant tu- berculosis and new oral anticoagulants on the model list. These applications challenge perceptions of essential medi- cines and rais e questions about how to address issues of cost and affordability for countries when making decisions at the global level.
